TP53 and neoplasm: Thus, combination therapy with Ad-p53 DCs and OBP-702 may be a promising antitumor strategy for inducing a strong antitumor effect by activating the presentation of p53 peptides in tumor cells and recruiting p53 peptide-targeting CTLs to tumors.